L. Kosse
Radboud University Nijmegen
Internal medicineIntensive care medicineProspective cohort studyExact testMedDRAEtanerceptSafety monitoringResponse rate (survey)DiseaseImmune-mediated inflammatory diseasesPharmacistDrugAdalimumabAdverse drug reactionIndependent researchDrug reactionMedical informationRheumatic diseaseFamily medicineClinical trialPharmacovigilanceMedicineCohort
12Publications
2H-index
9Citations
Publications 13
Newest
Background null Patient-reported outcomes (PROs) on adverse drug reactions (ADRs) are increasingly used in cohort event monitoring (CEM) to obtain a better understanding of patients' real-world experience with drugs. Despite the leading role for patients, little is known about their perspectives on CEM systems. null Research design and methods null In a cross-sectional open survey following the rationale of the Technology Acceptance Model, we aimed to obtain insight in patients' perspectives on ...
Source
Background: null Information on adverse drug reactions (ADRs) is generally clustered for all indications of a drug in the patient information leaflet. However, previous research has shown that participants of the Dutch Biologic Monitor (DBM) that use a biologic for their immune-mediated inflammatory disease (IMID) prefer to receive ADR information tailored to their own biologic an IMID (1). Currently, it is unclear whether the ADR profile of a specific biologic may differ between patients with d...
Source
Source
Source
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Rachel L. WestH-Index: 16
view all 9 authors...
Purpose To assess the agreement between patient-reported and health care provider-reported medical information in inflammatory bowel disease (IBD). Methods This multicentre, prospective, event monitoring study enrolled adult Crohn's disease (CD) and ulcerative colitis (UC) patients treated with a biological in four medical centres in the Netherlands. At two-monthly intervals, patients completed questionnaires on biological use, combination therapy and indication. The patient-reported information...
1 CitationsSource
#1L. KosseH-Index: 2
#2Naomi T. JessurunH-Index: 5
Last. Marieke de Vries (Radboud University Nijmegen)H-Index: 19
view all 10 authors...
BACKGROUND Biologics are used as effective therapeutics to treat a variety of diseases. Even though biologics are widely used, knowledge on the post-marketing experience of patients is limited. Therefore, a framework was established for a patient-reported outcome measure (PROM)-based drug safety monitoring system for ADRs attributed to biologics, known as the 'Dutch Biologic Monitor'. OBJECTIVE Generation of a multi-stakeholder perspective on the preferred setup, potential and added value of a P...
Source
#1L. KosseH-Index: 2
#2Gerda WeitsH-Index: 1
Last. Naomi T. JessurunH-Index: 5
view all 11 authors...
Patient-reported outcomes (PROs) are increasingly used in studies and medical practice to obtain information on patients’ perspectives towards their treatment or disease. However, most study outcom...
Source
#1L. KosseH-Index: 2
#2Naomi T. JessurunH-Index: 5
Last. Michael T. Nurmohamed (VUmc: VU University Medical Center)H-Index: 63
view all 7 authors...
OBJECTIVES: Assessment of the quality of patient-reported medical information in the Dutch Biologic Monitor and evaluation of the representativeness of the sampled participants. METHODS: Consecutive adult patients using a biologic DMARD (bDMARD) for an immune-mediated inflammatory disease were included in eight Dutch centres. For this substudy, data of 550 patients with inflammatory rheumatic diseases were used. Patient-reported bDMARD prescription, indication and combination therapy were verifi...
4 CitationsSource
Background: Patient-reported outcomes (PROs) are increasingly used in studies and medical practice to obtain information on patients’ perspectives towards their treatment or disease. However, study outcomes are primarily directed at and shared with healthcare professionals, even though the results may also be relevant for patients. Objectives: The objective of this study was to obtain insight in which results patients with immune-mediated inflammatory diseases (IMIDs), including inflammatory rhe...
Source
#1L. KosseH-Index: 2
#2Naomi T. JessurunH-Index: 5
Last. Harald E. Vonkeman (UT: University of Twente)H-Index: 25
view all 5 authors...
Background: Patient registries are a valuable tool to monitor a patient’s health status. However, these systems operate primarily from the healthcare provider (HCP) perspective, which makes it difficult to collect detailed information on the nature, frequency and personal impact of adverse drug reactions (ADRs). Objectives: Determining whether the distribution of patient-reported ADRs attributed to bDMARDs differs from ADR registrations by HCPs. Methods: Patient reported ADRs were derived from t...
Source